"Designing Growth Strategies is in our DNA"

Middle East & Africa Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI107919

 


To get information on various segments, share your queries with us

  ATTRIBUTE

  DETAILS

Study Period

2019-2030

Base Year

2022

Estimated Year

2023

Forecast Period

2023-2030

Historical Period

2019-2021

Growth Rate

CAGR of 5.7% from 2023 to 2030

Unit

Value (USD Billion)

Segmentation

Drug Class; Route of Administration; Distribution Channel; and Country/Sub-Region

By Drug Class

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

By Route of Administration

  • Oral
  • Injection
    • Intramuscular
    • Subcutaneous
    • Intravenous

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Country/ Sub-Region

  • GCC
  • South Africa
  • Rest of Middle East & Africa
  • 2019-2030
  • 2022
  • 2019-2021
  • 109
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann